Published in Physician Law Weekly, October 20th, 2004
It might get easier, thanks to a growing push by doctors and lawmakers to force drug companies to list on a national registry every study they conduct.
Currently, learning what experimental treatments are being tested for diseases ranging from arthritis to cancer to Parkinson's is a hit-or-miss proposition. It's one reason so few patients participate; even for cancer, where clinical trials are touted most, just 3% to 5% of patients are estimated to enroll.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.